AUA 2022

Integration of Lutetium into Clinical Practice: A Urologist's Perspective - Neal Shore

The Importance of Proper Transurethral Resection of Bladder Tumors (TURBT) in Bladder Cancer Treatment - Arnulf Stenzl

Women in Urologic Oncology: Past, Present, and Future - Alicia Morgans & Sam Chang

The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris

The Molecular Biology of Prostate Cancer - Christopher Barbieri

Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley

Women in Urologic Oncology - Anne K. Schuckman

Bladder Cancer Highlights - Stephen Williams

A Multidisciplinary Approach to Treating High-Grade Upper Tract Disease - A Case-Based Approach - Surena Matin, Jonathan Coleman, and Jean Hoffman-Censits

Antegrade Administration of Reverse Thermal Mitomycin Gel for Primary Chemoablation of Upper Tract Urothelial Carcinoma via Percutaneous Nephrostomy Tube - Katie Murray

Comparison of Dual Lumen Versus Single Lumen Flexible Ureteroscopes in Proximal Ureteral and Renal Stone Management - Rohit Bhatt

Thermal Effects of the Super-Pulse Thulium Fiber Laser During Ureteral Stone Laser Lithotripsy: An In Vivo Porcine Study - Kalon Morgan

Automated CT-based Stone Volume Determination: An Artificial Intelligence Algorithm to Calculate Kidney Stone Volume - Kalon Morgan

Comparison of Superpulse Thulium Fiber Laser vs. Holmium Laser for Ablation of Renal Calculi in an In Vivo Porcine Model - Andyshea Afyouni

A Probing Conversation on Prostate Cancer Diagnosis and the Potential of Liquid Biopsies and Polygenic Risk Scores - Sanoj Punnen

The Controversy Over Radical Cystectomy for N1 and N2 Bladder Cancer: Experts Weigh In - Brant Inman & Yair Lotan

Upper Tract Urothelial Carcinoma Highlights - Nima Almassi

Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross

Gender Differences in Bladder Cancer - Lauren Cooley

Adjuvant Therapy after Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma - Sima Porten

Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor

Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin

Why Not Biopsy? Challenging the Status Quo in Renal Mass Management - Jaime Landman

From Ultrasound to AI: Envisioning the Future of Stone Disease Treatment - Ralph Clayman

NCCN Guidelines Update on Selection of PSMA PET Imaging Agent in Patient Selection for Lutetium-177–PSMA-617 - Oliver Sartor

BCG Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer - Seth Lerner

Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray

Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen

The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore

AUA Guidelines on Localized Prostate Cancer - Stephen Boorjian & James Eastham

Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas

Early Triplet Combination Therapy Shows Increased Overall Survival: The ARASENS Trial - Tomasz Beer

New Orleans Restaurant Favorites - Plan Your AUA 2022 Dining Experiences - Oliver Sartor

Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore

ARASENS Trial Significantly Improves Overall Survival with Darolutamide in Combination with ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith

Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi